Humana PT Raised to $140.00 at Leerink Swann (HUM)
Stock analysts at Leerink Swann lifted their price objective on shares of Humana (NYSE:HUM) to $140.00 in a report issued on Friday. Leerink Swann’s price target would suggest a potential upside of 17.85% from the company’s current price.
Humana (NYSE:HUM) traded up 0.98% on Friday, hitting $118.80. The stock had a trading volume of 1,466,083 shares. Humana has a 52 week low of $89.89 and a 52 week high of $134.93. The stock’s 50-day moving average is $127.6 and its 200-day moving average is $114.. The company has a market cap of $18.325 billion and a price-to-earnings ratio of 17.66.
Humana (NYSE:HUM) last issued its quarterly earnings data on Wednesday, July 30th. The company reported $2.19 earnings per share (EPS) for the quarter, meeting the consensus estimate of $2.19. During the same quarter in the previous year, the company posted $2.63 earnings per share. Analysts expect that Humana will post $7.81 EPS for the current fiscal year.
A number of other analysts have also recently weighed in on HUM. Analysts at Zacks reiterated a “neutral” rating on shares of Humana in a research note on Thursday. They now have a $126.00 price target on the stock. Separately, analysts at Barclays raised their price target on shares of Humana from $120.00 to $128.00 in a research note on Thursday. They now have an “equal weight” rating on the stock. Finally, analysts at Credit Suisse reiterated a “neutral” rating on shares of Humana in a research note on Thursday. They now have a $123.00 price target on the stock, up previously from $121.00. Three research analysts have rated the stock with a sell rating, eleven have given a hold rating and four have assigned a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $125.75.
Humana Inc (NYSE:HUM) is a health care company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.